Thus, there is a consensus to avoid IM or any adjuvant treatment in this rare molecular subset of GIST.123Recent advances on the molecular background of SDH-deficient GISTs have shifted the therapy focus from the standard TKIs to other therapeutic strategies. The gene discussed is SDHB; the disease is gastrointestinal stromal tumor.